Novo Nordisk Financially Commits $1.2 Billion Toward New Danish Production Plant
The 430,000 square-foot finished production facility will house multiple product types within the rare disease sector, including hemophilia.
Novo Nordisk will be investing $1.2 billion toward the construction of entirely new production facility in Odense, Denmark.1 The investment holds even more weight, being that this will reportedly be the first time this century that the company is breaking ground in Denmark with the design of a new production site. Construction has officially begun and is anticipated to be completed by 2027.
The plant is expected to have a state-of-the-art finished production facility and warehouse that spans over 430,000 square feet in size. The area will house various product types within the rare disease space, including hemophilia.
"The facility will utilize advanced technology and innovative equipment to ensure the highest quality to patients and meet the growing global demand for our life-changing medicines,” said Henrik Wulff, executive vice president, product supply, quality & IT of Novo Nordisk. “We are proud to build on our heritage in Denmark and look forward to embarking on this journey in Odense, a well-connected city with a dynamic community and talented workforce."
The plan was for the plant to be created with the intention of preserving nature, which is why more than 4,000 new trees will be planted at the location. The buildings will have solar panels for on-site electricity generation, while the landscape will contain reused excess soil, wooden materials, and other sustainable resources to create lakes, forests and community spaces that will be open to the public.
The news follows Novo’s recent investment of $409 million toward a 570,000 square-foot quality control laboratory at its site in Hillerød, which is intended to be a central hub for quality control operations in Denmark.2 The lab will meet current and future good manufacturing practice (GMPs), while tackling current and future capacity expansions.
“This state-of-the-art quality control laboratory highlights Novo Nordisk's global growth journey and our dedication to innovation, commented Erik Lorin Rasmussen, senior vice president of product supply, aseptic manufacturing. “As we expand our manufacturing capacity and anticipate new products to meet the growing global demand, this new quality control facility will play an important role in ensuring the quality of our products and position us to meet the evolving requirements of patients and regulators.”
References
1. Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark. Novo Nordisk. December 16, 2024. Accessed December 17, 2024. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915079#
2. Novo Nordisk invests 2.9 billion DKK in a new state-of-the-art quality control laboratory in Hillerød, Denmark. Novo Nordisk. December 2, 2024. Accessed December 17, 2024. https://www.novonordisk.com/news-and-media/latest-news/quality-control-laboratory-hillerod-denmark.html
